Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clinical leaders

Clinical leaders

Company Status Country
Alizyme (LSE:AZM) Ph III U.K.
Antisoma (LSE:ASM) Ph III U.K.
Ark Therapeutics Ph III U.K.
Basilea Ph III Switzerland
BioTie (HSE:BTH1V) Ph III Finland
Cambridge Antibody (LSE:CAT; CATG) (A) Ph III U.K.
Curacyte Ph III Germany
GPC Biotech (FSE:GPC) Ph III Germany
GW Pharma (LSE:GWP) Ph III U.K.

Read the full 540 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE